Your browser is no longer supported. Please, upgrade your browser.
AVRO AVROBIO, Inc. daily Stock Chart
Index- P/E- EPS (ttm)-1.74 Insider Own0.10% Shs Outstand24.09M Perf Week-9.86%
Market Cap304.02M Forward P/E- EPS next Y-2.32 Insider Trans- Shs Float23.09M Perf Month-42.00%
Income-40.20M PEG- EPS next Q-0.57 Inst Own68.10% Short Float3.59% Perf Quarter-56.66%
Sales- P/S- EPS this Y-277.00% Inst Trans0.59% Short Ratio6.57 Perf Half Y-62.78%
Book/sh5.77 P/B2.19 EPS next Y26.30% ROA- Target Price40.50 Perf Year-
Cash/sh5.75 P/C2.19 EPS next 5Y- ROE- 52W Range12.96 - 53.70 Perf YTD-24.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.50% Beta-
Dividend %- Quick Ratio25.80 Sales past 5Y- Gross Margin- 52W Low-2.62% ATR1.87
Employees34 Current Ratio25.80 Sales Q/Q- Oper. Margin- RSI (14)28.20 Volatility7.56% 12.54%
OptionableNo Debt/Eq0.00 EPS Q/Q-69.00% Profit Margin- Rel Volume1.85 Prev Close13.70
ShortableYes LT Debt/Eq0.00 EarningsNov 08 Payout- Avg Volume125.99K Price12.62
Recom1.70 SMA20-20.76% SMA50-43.22% SMA200-57.72% Volume232,497 Change-7.88%
Oct-10-18Initiated Guggenheim Buy
Oct-02-18Reiterated H.C. Wainwright Buy $47 → $40
Sep-17-18Initiated H.C. Wainwright Buy $47
Jul-16-18Initiated Wells Fargo Outperform $40
Jul-16-18Initiated Wedbush Outperform $38
Jul-16-18Initiated Morgan Stanley Overweight $37
Jan-17-19 07:00AM  AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019 GlobeNewswire -7.88%
Jan-07-19 07:06AM  AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors GlobeNewswire -5.62%
Dec-21-18 10:00AM  AVROBIO, Inc. Added to NASDAQ Biotechnology Index GlobeNewswire -12.12%
12:41AM  Should You Avoid AVROBIO, Inc. (AVRO)? Insider Monkey
Dec-19-18 07:00AM  AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR RD 01 for the Treatment of Fabry Disease GlobeNewswire -7.88%
Dec-18-18 07:05AM  AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:00AM  AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires GlobeNewswire
Nov-28-18 01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
Nov-21-18 07:35AM  Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +9.16%
Nov-13-18 08:00AM  AVROBIO, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire +5.79%
Oct-04-18 04:01PM  AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference GlobeNewswire
Oct-01-18 07:01AM  AVROBIO Receives No Objection to Clinical Trial Application from Health Canada for AVR-RD-02 Gene Therapy for Gaucher Disease GlobeNewswire -51.55%
07:00AM  AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease GlobeNewswire
Aug-09-18 08:00AM  AVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Aug-08-18 08:00AM  AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-16-18 10:52AM  Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls Benzinga
Jun-27-18 08:00AM  AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors GlobeNewswire
Jun-25-18 04:30PM  AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option GlobeNewswire
Jun-22-18 08:13PM  [$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs The Wall Street Journal
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
08:42PM  AVROBIO, Inc. Announces Pricing of Initial Public Offering GlobeNewswire
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease. The company is also developing AVR-RD-02 for the treatment of type 1 gaucher disease; AVR-RD-03 for the treatment of pompe disease; and AVR-RD-04 for the treatment of cystinosis. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.